The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by rejecting AstraZeneca’s PT010, a close competitor. AZ has confirmed ...

So I am escaping to Italy, where — in my head — it is always summer, every bike is a gleaming Colnago Master, and one can ...